Correlagen Diagnostics Brings Genetic Testing for Primary Immunodeficiency to Clinical Practice

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2005--Correlagen Diagnostics, Inc. announced the availability of its molecular diagnostic testing services for primary immunodeficiency, which are performed in Correlagen's CLIA certified high complexity testing laboratory. Primary immunodeficiencies result from genetic defects in the immune system. They typically cause infections in young children, which are often life-threatening. Correlagen currently offers genetic testing for SCID (including XSCID), Hyper IgM Syndrome Type 2, X-linked Agammaglobulinemia, and Wiskott-Aldrich Syndrome.

"Primary immunodeficiency testing will help physicians make an early and accurate diagnosis so that appropriate treatment may be started before symptoms develop or become worse" said Raif Geha, M.D., Chief, Division of Immunology, Children's Hospital Boston, with whom Correlagen consulted in connection with the development of its clinical testing. "In SCID cases where treatment is generally bone marrow transplant, early diagnosis is critical since treatment outcome is better when the procedure is performed before the child experiences serious infection."

"Correlagen is proud to have brought this important line of genetic testing services to clinical practice so quickly." said Joyce Samet, Senior Vice President of Correlagen Diagnostics. "We will continue to use our automated high-throughput processes to make available high quality genetic testing for primary immunodeficiency syndromes and for other diseases where knowledge of patient genotype will facilitate diagnosis and treatment."

Correlagen Diagnostics, Inc. specializes in developing and commercializing DNA-based testing that assists in the diagnosis of genetic diseases through sequence variant detection. Correlagen selects genes for testing based on clinical relevance and provides in-depth interpretation of sequencing results through its innovative technologies, which include a dynamic database of gene variants and an automated rules-based reporting system. By using this unique approach to genetic testing, Correlagen is able to provide updated interpretations to physicians and their patients as the knowledge of genetic variation and its significance to diagnosis and treatment evolves.

Correlagen Diagnostics, Inc., develops and commercializes genetic testing services, using a high throughput automated approach that incorporates sequencing, variant analysis and information technology. By focusing on Genes That Matter(TM) --genes where variation is correlated with disease and where testing would impact diagnosis and treatment--, Correlagen is accelerating and increasing the use of genetic testing in clinical practice. Correlagen Diagnostics is based in Cambridge, Massachusetts. www.correlagen.com

Correlagen Diagnostics, Inc.
Joyce S. Samet
617-577-0152
jsamet@correlagen.com